v3.26.1
Net Earnings (Loss) Per Share
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Net Earnings (Loss) Per Share

Note 11 - Net Earnings (Loss) Per Share

 

Basic earnings (loss) per share excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted earnings (loss) per share also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

 

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):

 

   June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
   For the three months ended   For the six months ended 
   June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
Loss from continuing operations after income taxes  $(3,051)  $(4,472)  $(8,226)  $(9,150)
Income from discontinued operations, net of tax   -    -    -    8,644 
Net loss  $(3,051)  $(4,472)  $(8,226)  $(506)
Weighted average common shares outstanding:                    
Basic   14,016    4,154    13,171    3,840 
Diluted   14,016    4,154    13,171    3,840 
Net earnings (loss) per share:                    
Loss from continuing operations, basic and diluted  $(0.22)  $(1.08)  $(0.62)  $(2.38)
Income from discontinued operations, basic and diluted  $-   $-   $-   $2.25 
Net loss (earnings) per share, basic and diluted  $(0.22)  $(1.08)  $(0.62)  $(0.13)

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):

 

Anti-dilutive securities  June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
   For the three months ended   For the six months ended 
Anti-dilutive securities  June 30, 2026   June 30, 2025   June 30, 2026   June 30, 2025 
Common stock purchase warrants   997    174    997    174 
Stock options   478    445    478    445 
Convertible notes   13,773    -    13,773    - 
Anti-dilutive securities   15,248    619    15,248    619